International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

Le Cesne, Axel
Bauer, Sebastian
Demetri, George D
Han, Guangyang
Dezzani, Luca
Ahmad, Qasim
Blay, Jean-Yves
Judson, Ian
Schoeffski, Patrick
Aglietta, Massimo
Hohenberger, Peter
Gelderblom, Hans

August 2019

BACKGROUND: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advan...

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Graaf, W.T.A. van der
Blay, J.Y.
Chawla, S.P.
Kim, D.W.
Bui-Nguyen, B.
Casali, P.G.
Schoffski, P.
Aglietta, M.
Staddon, A.P.
Beppu, Y.
Cesne, A. le
Gelderblom, H.
Judson, I.R.
Araki, N.
Ouali, M.
Marreaud, S.
Hodge, R.
Dewji, M.R.
Coens, C.
Demetri, G.D.
Fletcher, C.D.
Tos, A.P. Dei
Hohenberger, P.

January 2012

BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patie...

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European -rganisation for Research and Truatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Benson, Charlotte
Chawla, Sant
Gil, Thierry
Piperno-Neumann, Sophie
Marreaud, Sandrine
Dewji, Mohammed Raza
Van Der Graaf, Winette Ta A
Ray-Coquard, Isabelle
Sleijfer, Stefan
Litière, Saskia
Blay, Jean Yves
Le Cesne, Axel Le A.
Papai, Zsuzsanna
Judson, Ian
Schöffski, Patrick

July 2016

Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They ...

Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.

June 2017

none19openJavier Martin Broto; Silvia Stacchiotti; Antonio Lopez-Pousa; Andres Redondo; Daniel Berna...

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial

November 2020

none30siBackground: Extraskeletal myxoid chondrosarcoma is a rare sarcoma with low sensitivity to cy...

Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.

June 2017

none20openAnna Maria Frezza; Naofumi Asano; Robin Jones; Ravin Ratan; Pawel Teterycz; Hans Gelderblo...

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Sleijfer, Stefan
Ray-Coquard, I
Papai, Z
le Cesne, A
Scurr, M
Schoffski, P
Collin, F
Pandite, L
Marreaud, S
De Brauwer, A
Glabbeke, M
Verweij, Jaap
Blay, JY

January 2009

Purpose Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiog...

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

Kollar, A.
Jones, R.L.
Stacchiotti, S.
Gelderblom, H.
Guida, M.
Grignani, G.
Steeghs, N.
Safwat, A.
Katz, D.
Duffaud, F.
Sleijfer, S.
Graaf, W.T.A. van der
Touati, N.
Litiere, S.
Marreaud, S.
Gronchi, A.
Kasper, B.

January 2017

Contains fulltext : 170335.pdf (publisher's version ) (Open Access)BACKGROUND: Paz...

Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study

김지형
김효송

June 2020

Background: Pazopanib is the only tyrosine kinase inhibitor approved for the treatment of patients w...

Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

SEZGİN GÖKSU, SEMA
PAYDAŞ, SEMRA
Akgul, Fahri
Derin, Sumeyye
Turhal, Serdar
Artac, Mehmet
Dal, Pinar
Sunar, Veli
Seker, Mehmet Metin
Gunaydin, Ulug Mutlu
Ozveren, Ahmet
Bahceci, Aykut
Sakalar, Teoman
Sahin, Suleyman
Koral, Lokman
Acar, Ramazan
Unal, Olcun Umit
Besiroglu, Mehmet
Erdem, Dilek
Demir, Hacer
Ozkul, Ozlem
Sakin, Abdullah
Gumusay, Ozge
Cinkir, Havva Yesil
Menekse, Serkan
Guc, Zeynep Gulsum
Karaca, Mustafa
Demiray, Atike Gokcen
Ozyukseler, Deniz Tataroglu
Erol, Cihan
Yekeduz, Emre
Ergun, Yakup
BİLİCİ, Ahmet
Koca, Sinan
Karaagac, Mustafa
Aydin, Sabin Goktas
Eraslan, Emrah
Kaplan, Muhammed Ali
Ocak, Birol

September 2023

Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated wi...

Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

Schulte, Brian
Mohindra, Nisha
Milhem, Mohammed
Attia, Steven
Robinson, Steven
Monga, Varun
Hirbe, Angela C
Oppelt, Peter
Charlson, John
Helenowski, Irene
Abbinanti, Susan
Cehic, Rasima
Okuno, Scott
Van Tine, Brian A
Agulnik, Mark

January 2021

BACKGROUND: Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs P...

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.

Jones, RL
Ravi, V
Brohl, AS
Chawla, S
Ganjoo, KN
Italiano, A
Attia, S
Burgess, MA
Thornton, K
Cranmer, LD
Cheang, MCU
Liu, L
Robertson, L
Adams, B
Theuer, C
Maki, RG

July 2022

Importance: Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib p...

Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California

Tiffany Seto
Mee-Na Song
Maily Trieu
Jeanette Yu
Manpreet Sidhu
Chi-Mei Liu
Danny Sam
Minggui Pan

March 2019

Background: Pazopanib was approved for advanced soft tissue sarcoma as a second- or third-line thera...

Preoperative therapy with pazopanib in high-risk soft tissue sarcoma : a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)

Ronellenfitsch, Ulrich
Dimitrakopoulou-Strauss, Antonia
Jakob, Jens
Kasper, Bernd
Nowak, Kai
Pilz, Lothar R.
Attenberger, Ulrike
Gaiser, Timo
Egerer, Gerlinde
Fröhling, Stefan
Derigs, Hans-Günter
Schwarzbach, Matthias
Hohenberger, Peter

January 2016

Introduction: For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radio...

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Benson, C
Ray-Coquard, I
Sleijfer, S
Litiere, S
Blay, J-Y
Le Cesne, A
Papai, Z
Judson, I
Schöffski, Patrick
Chawla, S
Gil, T
Piperno-Neumann, S
Marreaud, S
Dewji, MR
van der Graaf, WTA

January 2016

BACKGROUND: Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They...

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

Le Cesne, Axel
Bauer, Sebastian
Demetri, George D
Han, Guangyang
Dezzani, Luca
Ahmad, Qasim
Blay, Jean-Yves
Judson, Ian
Schoeffski, Patrick
Aglietta, Massimo
Hohenberger, Peter
Gelderblom, Hans

August 2019

BACKGROUND: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advan...

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Graaf, W.T.A. van der
Blay, J.Y.
Chawla, S.P.
Kim, D.W.
Bui-Nguyen, B.
Casali, P.G.
Schoffski, P.
Aglietta, M.
Staddon, A.P.
Beppu, Y.
Cesne, A. le
Gelderblom, H.
Judson, I.R.
Araki, N.
Ouali, M.
Marreaud, S.
Hodge, R.
Dewji, M.R.
Coens, C.
Demetri, G.D.
Fletcher, C.D.
Tos, A.P. Dei
Hohenberger, P.

January 2012

BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patie...

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European -rganisation for Research and Truatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Benson, Charlotte
Chawla, Sant
Gil, Thierry
Piperno-Neumann, Sophie
Marreaud, Sandrine
Dewji, Mohammed Raza
Van Der Graaf, Winette Ta A
Ray-Coquard, Isabelle
Sleijfer, Stefan
Litière, Saskia
Blay, Jean Yves
Le Cesne, Axel Le A.
Papai, Zsuzsanna
Judson, Ian
Schöffski, Patrick

July 2016

Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They ...

Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.

June 2017

none19openJavier Martin Broto; Silvia Stacchiotti; Antonio Lopez-Pousa; Andres Redondo; Daniel Berna...

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial

November 2020

none30siBackground: Extraskeletal myxoid chondrosarcoma is a rare sarcoma with low sensitivity to cy...

Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.

June 2017

none20openAnna Maria Frezza; Naofumi Asano; Robin Jones; Ravin Ratan; Pawel Teterycz; Hans Gelderblo...

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Sleijfer, Stefan
Ray-Coquard, I
Papai, Z
le Cesne, A
Scurr, M
Schoffski, P
Collin, F
Pandite, L
Marreaud, S
De Brauwer, A
Glabbeke, M
Verweij, Jaap
Blay, JY

January 2009

Purpose Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiog...

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

Kollar, A.
Jones, R.L.
Stacchiotti, S.
Gelderblom, H.
Guida, M.
Grignani, G.
Steeghs, N.
Safwat, A.
Katz, D.
Duffaud, F.
Sleijfer, S.
Graaf, W.T.A. van der
Touati, N.
Litiere, S.
Marreaud, S.
Gronchi, A.
Kasper, B.

January 2017

Contains fulltext : 170335.pdf (publisher's version ) (Open Access)BACKGROUND: Paz...

Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study

김지형
김효송

June 2020

Background: Pazopanib is the only tyrosine kinase inhibitor approved for the treatment of patients w...

Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

SEZGİN GÖKSU, SEMA
PAYDAŞ, SEMRA
Akgul, Fahri
Derin, Sumeyye
Turhal, Serdar
Artac, Mehmet
Dal, Pinar
Sunar, Veli
Seker, Mehmet Metin
Gunaydin, Ulug Mutlu
Ozveren, Ahmet
Bahceci, Aykut
Sakalar, Teoman
Sahin, Suleyman
Koral, Lokman
Acar, Ramazan
Unal, Olcun Umit
Besiroglu, Mehmet
Erdem, Dilek
Demir, Hacer
Ozkul, Ozlem
Sakin, Abdullah
Gumusay, Ozge
Cinkir, Havva Yesil
Menekse, Serkan
Guc, Zeynep Gulsum
Karaca, Mustafa
Demiray, Atike Gokcen
Ozyukseler, Deniz Tataroglu
Erol, Cihan
Yekeduz, Emre
Ergun, Yakup
BİLİCİ, Ahmet
Koca, Sinan
Karaagac, Mustafa
Aydin, Sabin Goktas
Eraslan, Emrah
Kaplan, Muhammed Ali
Ocak, Birol

September 2023

Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated wi...

Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

Schulte, Brian
Mohindra, Nisha
Milhem, Mohammed
Attia, Steven
Robinson, Steven
Monga, Varun
Hirbe, Angela C
Oppelt, Peter
Charlson, John
Helenowski, Irene
Abbinanti, Susan
Cehic, Rasima
Okuno, Scott
Van Tine, Brian A
Agulnik, Mark

January 2021

BACKGROUND: Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs P...

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.

Jones, RL
Ravi, V
Brohl, AS
Chawla, S
Ganjoo, KN
Italiano, A
Attia, S
Burgess, MA
Thornton, K
Cranmer, LD
Cheang, MCU
Liu, L
Robertson, L
Adams, B
Theuer, C
Maki, RG

July 2022

Importance: Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib p...

Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California

Tiffany Seto
Mee-Na Song
Maily Trieu
Jeanette Yu
Manpreet Sidhu
Chi-Mei Liu
Danny Sam
Minggui Pan

March 2019

Background: Pazopanib was approved for advanced soft tissue sarcoma as a second- or third-line thera...

Preoperative therapy with pazopanib in high-risk soft tissue sarcoma : a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)

Ronellenfitsch, Ulrich
Dimitrakopoulou-Strauss, Antonia
Jakob, Jens
Kasper, Bernd
Nowak, Kai
Pilz, Lothar R.
Attenberger, Ulrike
Gaiser, Timo
Egerer, Gerlinde
Fröhling, Stefan
Derigs, Hans-Günter
Schwarzbach, Matthias
Hohenberger, Peter

January 2016

Introduction: For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radio...

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Benson, C
Ray-Coquard, I
Sleijfer, S
Litiere, S
Blay, J-Y
Le Cesne, A
Papai, Z
Judson, I
Schöffski, Patrick
Chawla, S
Gil, T
Piperno-Neumann, S
Marreaud, S
Dewji, MR
van der Graaf, WTA

January 2016

BACKGROUND: Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They...

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

Le Cesne, Axel
Bauer, Sebastian
Demetri, George D
Han, Guangyang
Dezzani, Luca
Ahmad, Qasim
Blay, Jean-Yves
Judson, Ian
Schoeffski, Patrick
Aglietta, Massimo
Hohenberger, Peter
Gelderblom, Hans

August 2019

BACKGROUND: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advan...

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Graaf, W.T.A. van der
Blay, J.Y.
Chawla, S.P.
Kim, D.W.
Bui-Nguyen, B.
Casali, P.G.
Schoffski, P.
Aglietta, M.
Staddon, A.P.
Beppu, Y.
Cesne, A. le
Gelderblom, H.
Judson, I.R.
Araki, N.
Ouali, M.
Marreaud, S.
Hodge, R.
Dewji, M.R.
Coens, C.
Demetri, G.D.
Fletcher, C.D.
Tos, A.P. Dei
Hohenberger, P.

January 2012

BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patie...

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European -rganisation for Research and Truatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Benson, Charlotte
Chawla, Sant
Gil, Thierry
Piperno-Neumann, Sophie
Marreaud, Sandrine
Dewji, Mohammed Raza
Van Der Graaf, Winette Ta A
Ray-Coquard, Isabelle
Sleijfer, Stefan
Litière, Saskia
Blay, Jean Yves
Le Cesne, Axel Le A.
Papai, Zsuzsanna
Judson, Ian
Schöffski, Patrick

July 2016

Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They ...

International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.

Abstract

Extracted data

International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.

Abstract

Extracted data

Related items

Related items